No Data
No Data
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
Gyre Therapeutics Low Blood Platelet Treatment Approved in China
Express News | Gyre Therapeutics Announces China’s Nmpa Approval of Avatrombopag Maleate Tablets for the Treatment of Cld-Associated Thrombocytopenia
Gyre Therapeutics(GYRE.US) Director Sells US$41,437.81 in Common Stock
$Gyre Therapeutics(GYRE.US)$ Director USMAN NASSIM sold 3,452 shares of common stock on Jun 28, 2024 at an average price of $12.004 for a total value of $41,437.81.Source: Announcement What is stateme
Form 144 | Gyre Therapeutics(GYRE.US) Director Proposes to Sell 148.1K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Gyre Therapeutics(GYRE.US)$ Director NASSIM USMAN intends to sell 12,200 shares of its common stock on Jul 1, with a total market value of approximately $148.1K. NASS
No Data